185 related articles for article (PubMed ID: 31124200)
21. Intermittent Vismodegib Therapy in Basal Cell Nevus Syndrome.
Yang X; Dinehart SM
JAMA Dermatol; 2016 Feb; 152(2):223-4. PubMed ID: 26509945
[No Abstract] [Full Text] [Related]
22. Persistent alopecia induced by vismodegib.
Alkeraye S; Maire C; Desmedt E; Templier C; Mortier L
Br J Dermatol; 2015 Jun; 172(6):1671-1672. PubMed ID: 25546344
[No Abstract] [Full Text] [Related]
23. Vismodegib for the treatment of aggressive basal cell carcinoma in a patient unable to swallow pills.
Umanoff N; Sarbib K; Mulvaney M; Iorizzo L
Dermatol Surg; 2015 Mar; 41(3):433-5. PubMed ID: 25738448
[No Abstract] [Full Text] [Related]
24. Vismodegib (Erivedge) for basal cell carcinoma.
Med Lett Drugs Ther; 2012 Jul; 54(1394):53-4. PubMed ID: 22777303
[No Abstract] [Full Text] [Related]
25. Fast growing melanoma following treatment with vismodegib for locally advanced basal cell carcinomas: report of two cases.
Giuffrida R; Kashofer K; Dika E; Patrizi A; Baraldi C; Di Meo N; Zalaudek I
Eur J Cancer; 2018 Mar; 91():177-179. PubMed ID: 29373258
[No Abstract] [Full Text] [Related]
26. Comparison of daily dosing versus Monday through Friday dosing of vismodegib for locally advanced basal cell carcinoma and basal cell nevus syndrome: A retrospective case series.
Wong C; Poblete-Lopez C; Vidimos A
J Am Acad Dermatol; 2020 Jun; 82(6):1539-1542. PubMed ID: 32092372
[No Abstract] [Full Text] [Related]
27. PRISModegib: the use of the PRISM test to assess the health-related quality of life of patients with locally advanced basal cell carcinoma undergoing Hedgehog pathway inhibitor therapy.
Gualdi G; Moro R; Regina V; Caravello S; Monari P; Calzavara-Pinton PG
Br J Dermatol; 2019 Aug; 181(2):406-407. PubMed ID: 30737996
[No Abstract] [Full Text] [Related]
28. Multiple highly and moderately differentiated squamous cell carcinomas of the skin during vismodegib treatment of inoperable basal cell carcinoma.
Orouji A; Goerdt S; Utikal J; Leverkus M
Br J Dermatol; 2014 Aug; 171(2):431-3. PubMed ID: 24446722
[No Abstract] [Full Text] [Related]
29. [Vismodegib Therapy for Periocular Basal Cell Carcinoma].
Keserü M; Green S; Dulz S
Klin Monbl Augenheilkd; 2017 Jan; 234(1):64-69. PubMed ID: 28135752
[No Abstract] [Full Text] [Related]
30. Acute pancreatitis after vismodegib for basal cell carcinoma: a causal relation?
Velter C; Blanc J; Robert C
Eur J Cancer; 2019 Sep; 118():67-69. PubMed ID: 31325874
[No Abstract] [Full Text] [Related]
31. Drug reaction with eosinophilia and systemic symptoms in metastatic basal cell carcinoma treated with vismodegib.
Thomas CL; Arasaratnam M; Carlos G; Parasyn A; Baumgart KW; Fernandez-Penas P; Marx G
Australas J Dermatol; 2017 Feb; 58(1):69-70. PubMed ID: 28195319
[No Abstract] [Full Text] [Related]
32. Efficacy of Vismodegib (Erivedge) for Basal Cell Carcinoma Involving the Orbit and Periocular Area.
Demirci H; Worden F; Nelson CC; Elner VM; Kahana A
Ophthalmic Plast Reconstr Surg; 2015; 31(6):463-6. PubMed ID: 25675162
[TBL] [Abstract][Full Text] [Related]
33. Occurrence of vismodegib-induced cramps (muscular spasms) in the treatment of basal cell carcinoma: A prospective study in 30 patients.
Girard E; Lacour A; Abi Rached H; Ramdane N; Templier C; Dziwniel V; Desmedt E; Le Rhun E; Mortier L
J Am Acad Dermatol; 2018 Jun; 78(6):1213-1216.e2. PubMed ID: 29203435
[No Abstract] [Full Text] [Related]
34. Dysgeusia and weight loss under treatment with vismodegib: benefit of nutritional management.
Le Moigne M; Saint-Jean M; Jirka A; Quéreux G; Peuvrel L; Brocard A; Gaultier A; Khammari A; Darmaun D; Dréno B
Support Care Cancer; 2016 Apr; 24(4):1689-95. PubMed ID: 26416491
[TBL] [Abstract][Full Text] [Related]
35. Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma.
Lyseng-Williamson KA; Keating GM
Am J Clin Dermatol; 2013 Feb; 14(1):61-4. PubMed ID: 23329081
[TBL] [Abstract][Full Text] [Related]
36. Cannabis for Vismodegib-Related Muscle Cramps in a Patient With Advanced Basal Cell Carcinoma.
Kutiel TS; Vornicova O; Bar-Sela G
J Pain Symptom Manage; 2018 May; 55(5):e1-e2. PubMed ID: 29454899
[No Abstract] [Full Text] [Related]
37. Complete response is reversible upon vismodegib withdrawal and re-inducible upon vismodegib rechallenge in a patient with locally advanced basal cell carcinoma.
Dessinioti C; Plaka M; Dimitrakopoulou A; Stratigos AJ
J Eur Acad Dermatol Venereol; 2019 May; 33(5):e187-e188. PubMed ID: 30653740
[No Abstract] [Full Text] [Related]
38. Development of squamous cell carcinoma into basal cell carcinoma under treatment with Vismodegib.
Saintes C; Saint-Jean M; Brocard A; Peuvrel L; Renaut JJ; Khammari A; Quéreux G; Dréno B
J Eur Acad Dermatol Venereol; 2015 May; 29(5):1006-9. PubMed ID: 24980899
[TBL] [Abstract][Full Text] [Related]
39. Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial.
Basset-Séguin N; Hauschild A; Kunstfeld R; Grob J; Dréno B; Mortier L; Ascierto PA; Licitra L; Dutriaux C; Thomas L; Meyer N; Guillot B; Dummer R; Arenberger P; Fife K; Raimundo A; Dika E; Dimier N; Fittipaldo A; Xynos I; Hansson J
Eur J Cancer; 2017 Nov; 86():334-348. PubMed ID: 29073584
[TBL] [Abstract][Full Text] [Related]
40. Histopathology of Basal Cell Carcinoma After Treatment With Vismogedib.
Tang JC; Buckel L; Hanke CW
J Drugs Dermatol; 2019 Feb; 18(2):136-138. PubMed ID: 30794363
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
